Skip to content
10-K

Annual Report

TCR2 Therapeutics Inc.

0000950170-23-009312

← back to feed
Filed
Mar 23, 2023 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding FY 2022 · Mar 5, 2023 39.24M sh
Shares Diluted FY 2022 · Dec 31, 2022 38.63M sh
Shares Diluted FY 2022 · Dec 31, 2021 37.94M sh
Capex FY 2022 · Dec 31, 2022 $15.12M
Capex FY 2022 · Dec 31, 2021 $11.1M
Operating Cash Flow FY 2022 · Dec 31, 2022 −$101.46M
Operating Cash Flow FY 2022 · Dec 31, 2021 −$81.6M
Cash And Equivalents FY 2022 · Dec 31, 2022 $32.75M
Cash And Equivalents FY 2022 · Dec 31, 2021 $222.56M
Stockholders Equity FY 2022 · Dec 31, 2022 $140.86M
Stockholders Equity FY 2022 · Dec 31, 2021 $281.48M
Stockholders Equity FY 2022 · Dec 31, 2020 $236.55M
Current Liabilities FY 2022 · Dec 31, 2022 $64.06M
Current Liabilities FY 2022 · Dec 31, 2021 $18.61M
Total Liabilities FY 2022 · Dec 31, 2022 $67.38M
Total Liabilities FY 2022 · Dec 31, 2021 $41.89M
Current Assets FY 2022 · Dec 31, 2022 $177.62M
Current Assets FY 2022 · Dec 31, 2021 $276.13M
Total Assets FY 2022 · Dec 31, 2022 $208.24M
Total Assets FY 2022 · Dec 31, 2021 $323.37M
Eps Diluted FY 2022 · Dec 31, 2022 −$3.93
Eps Diluted FY 2022 · Dec 31, 2021 −$2.63
Eps Basic FY 2022 · Dec 31, 2022 −$3.93
Eps Basic FY 2022 · Dec 31, 2021 −$2.63
Sga Expense FY 2022 · Dec 31, 2022 $24.44M
Sga Expense FY 2022 · Dec 31, 2021 $22.5M
Rd Expense FY 2022 · Dec 31, 2022 $98.64M
Rd Expense restated FY 2022 · Dec 31, 2021 $73.58M
Net Income FY 2022 · Dec 31, 2022 −$151.82M
Net Income FY 2022 · Dec 31, 2021 −$99.81M
Operating Income FY 2022 · Dec 31, 2022 −$153.5M
Operating Income FY 2022 · Dec 31, 2021 −$99.74M